Literature DB >> 16085675

Gene transfer of CFTR to airway epithelia: low levels of expression are sufficient to correct Cl- transport and overexpression can generate basolateral CFTR.

Sara L Farmen1, Philip H Karp, Philip Ng, Donna J Palmer, David R Koehler, Jim Hu, Arthur L Beaudet, Joseph Zabner, Michael J Welsh.   

Abstract

Gene transfer of CFTR cDNA to airway epithelia is a promising approach to treat cystic fibrosis (CF). Most gene transfer vectors use strong viral promoters even though the endogenous CFTR promoter is very weak. To learn whether expressing CFTR at a low level in a fraction of cells would correct Cl(-) transport, we mixed freshly isolated wild-type and CF airway epithelial cells in varying proportions and generated differentiated epithelia. Epithelia with approximately 20% wild-type cells generated approximately 70% the transepithelial Cl(-) current of epithelia containing 100% wild-type cells. These data were nearly identical to those previously obtained with CFTR expressed under control of a strong promoter in a CF epithelial cell line. We also tested high level CFTR expression using the very strong cytomegalovirus (CMV) promoter as well as the cytokeratin-18 (K18) promoter. In differentiated airway epithelia, the CMV promoter generated 50-fold more transgene expression than the K18 promoter, but the K18 promoter generated more transepithelial Cl(-) current at high vector doses. Using functional studies, we found that with marked overexpression, some CFTR channels were present in the basolateral membrane where they shunted Cl(-) flow, thereby reducing net transepithelial Cl(-) transport. These results suggest that very little CFTR is required in a fraction of CF epithelial cells to complement Cl(-) transport because transepithelial Cl(-) flow is limited at the basolateral membrane. Thus they suggest a broad leeway in promoter strength for correcting the CF gene transfer, although at very high expression levels CFTR may be mislocalized to the basolateral membrane.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16085675     DOI: 10.1152/ajplung.00049.2005

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  47 in total

Review 1.  Cystic fibrosis transmembrane conductance regulator dysfunction and its treatment.

Authors:  Jeremy Hull
Journal:  J R Soc Med       Date:  2012-06       Impact factor: 5.344

2.  Cell surface rescue of kidney anion exchanger 1 mutants by disruption of chaperone interactions.

Authors:  Sian T Patterson; Reinhart A F Reithmeier
Journal:  J Biol Chem       Date:  2010-07-13       Impact factor: 5.157

3.  Respiratory syncytial virus engineered to express the cystic fibrosis transmembrane conductance regulator corrects the bioelectric phenotype of human cystic fibrosis airway epithelium in vitro.

Authors:  Anna R Kwilas; Mark A Yednak; Liqun Zhang; Rachael Liesman; Peter L Collins; Raymond J Pickles; Mark E Peeples
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

4.  Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes.

Authors:  Katsuyuki Mitomo; Uta Griesenbach; Makoto Inoue; Lucinda Somerton; Cuixiang Meng; Eiji Akiba; Toshiaki Tabata; Yasuji Ueda; Gad M Frankel; Raymond Farley; Charanjit Singh; Mario Chan; Felix Munkonge; Andrea Brum; Stefania Xenariou; Sara Escudero-Garcia; Mamoru Hasegawa; Eric W F W Alton
Journal:  Mol Ther       Date:  2010-03-23       Impact factor: 11.454

5.  Correlating Cystic Fibrosis Transmembrane Conductance Regulator Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis.

Authors:  Allison F McCague; Karen S Raraigh; Matthew J Pellicore; Emily F Davis-Marcisak; Taylor A Evans; Sangwoo T Han; Zhongzhou Lu; Anya T Joynt; Neeraj Sharma; Carlo Castellani; Joseph M Collaco; Mary Corey; Michelle H Lewis; Chris M Penland; Johanna M Rommens; Anne L Stephenson; Patrick R Sosnay; Garry R Cutting
Journal:  Am J Respir Crit Care Med       Date:  2019-05-01       Impact factor: 21.405

6.  Transcriptional targeting in the airway using novel gene regulatory elements.

Authors:  Erin R Burnight; Guoshun Wang; Paul B McCray; Patrick L Sinn
Journal:  Am J Respir Cell Mol Biol       Date:  2012-03-23       Impact factor: 6.914

7.  Optimization of Recombinant Adeno-Associated Virus-Mediated Expression for Large Transgenes, Using a Synthetic Promoter and Tandem Array Enhancers.

Authors:  Ziying Yan; Xingshen Sun; Zehua Feng; Guiying Li; John T Fisher; Zoe A Stewart; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2015-04-20       Impact factor: 5.695

8.  Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease.

Authors:  Jesús M Banales; Tatyana V Masyuk; Pamela S Bogert; Bing Q Huang; Sergio A Gradilone; Seung-Ok Lee; Angela J Stroope; Anatoliy I Masyuk; Juan F Medina; Nicholas F LaRusso
Journal:  Am J Pathol       Date:  2008-11-06       Impact factor: 4.307

9.  Correction of Airway Stem Cells: Genome Editing Approaches for the Treatment of Cystic Fibrosis.

Authors:  Nicholas E King; Shingo Suzuki; Cristina Barillà; Finn J Hawkins; Scott H Randell; Susan D Reynolds; Barry R Stripp; Brian R Davis
Journal:  Hum Gene Ther       Date:  2020-09-08       Impact factor: 5.695

10.  CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium.

Authors:  Liqun Zhang; Brian Button; Sherif E Gabriel; Susan Burkett; Yu Yan; Mario H Skiadopoulos; Yan Li Dang; Leatrice N Vogel; Tristan McKay; April Mengos; Richard C Boucher; Peter L Collins; Raymond J Pickles
Journal:  PLoS Biol       Date:  2009-07-21       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.